Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00460 SIHUAN PHARM
RTNominal unchange0.510 0.000 (0.000%)
Others

29/09/2021 17:50

Sihuan Pharm (00460) to collaborate with WuXi XDC

[ET Net News Agency, 29 September 2021] Sihuan Pharmaceutical Holdings Group Ltd.
(00460) said Xuanzhu Kangming, the large molecule biological drug platform of its
subsidiary Xuanzhu Biopharm, and WuXi XDC have reached a collaboration on the development
and manufacturing of an innovative oncology drug KM501, a bispecific antibody drug
conjugate (ADC).
According to the collaboration agreement, Xuanzhu Kangming will promote the R&D process
of KM501 bispecific ADC through the integrated CMC service of WuXi XDC. WuXi XDC will
provide end-to-end services such as antibody, linker, payload, analytical method and
process development, development and manufacturing of conjugate drug substances and drug
products to support the IND application of KM501 bispecific ADC. (RC)

Back to Others

Remark: Real time quote last updated: 19/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.